Molecular Pathways of Ac-SDKP in Fibrosis Suppression and Inflammatory Regulation

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Background on Ac-SDKP

Thymosin Beta-4 (Tβ4) is a naturally occurring peptide consisting of 43 amino acids. From this sequence, the N-terminal tetrapeptide fragment Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is generated. Ac-SDKP has been shown to play an important regulatory role in inflammation and fibrosis across multiple organ systems.

Renal Protection and Fibrosis Reduction

Research demonstrates that Ac-SDKP, particularly in combination with ACE inhibitors (ACEi), can reduce kidney fibrosis. ACEi therapy alone or alongside Ac-SDKP prevents downregulation of antifibrotic microRNAs such as miR-29 and miR-let-7, which are typically suppressed during TGF-β stimulation. Restoration of this microRNA cross-talk is critical in countering mesenchymal transition and fibrogenic processes.

In diabetic mouse models, ACEi and Ac-SDKP significantly lowered levels of profibrotic markers, including DPP-4, TGFβR1, phosphorylated Smad3, FSP-1, α-SMA, collagen I, and fibronectin. This effect was not observed with angiotensin receptor blockers (ARB), highlighting ACEi’s unique role in promoting Ac-SDKP-mediated renal protection.

These findings indicate that Ac-SDKP enhances ACEi’s antifibrotic capacity, primarily by restoring antifibrotic microRNA signaling and reducing mesenchymal transformation.

Read More:  peptide frontiers.

Anti-Fibrotic Actions in Cardiac and Pulmonary Tissue

Endogenous Role

Endogenous Ac-SDKP regulates collagen content under physiological conditions. Experimental depletion of basal Ac-SDKP levels promoted cardiac and renal fibrosis and accelerated collagen deposition when combined with profibrotic stimuli such as angiotensin II.

Pulmonary Fibrosis

Ac-SDKP has been shown to attenuate TGF-β1 and receptor expression, collagen synthesis, and myofibroblast differentiation in models of silicosis. By blunting Smad signaling and enhancing apoptosis in fibroblasts exposed to silica and TGF-β1, Ac-SDKP provides a protective role against lung fibrosis.

Cardiac Fibrosis

Ac-SDKP prevents differentiation of cardiac fibroblasts into collagen-producing myofibroblasts. It reduces radiation-induced cardiomyocyte apoptosis, fibrosis, and macrophage-driven inflammatory activity. Furthermore, Ac-SDKP suppresses fibrotic mediators such as α-SMA, MRTF-A, and SRF, and blocks signaling via TGF-β1 and ERK1/2 pathways.

Stem Cell Regulation

Initially, Ac-SDKP was identified as an inhibitor of bone marrow-derived stem cell differentiation by halting the G1-S phase cell cycle transition. This suggests potential use as a supportive therapy during chemotherapy, protecting hematopoietic stem cells by maintaining them in a quiescent state.

Immunomodulatory and Anti-Inflammatory Effects

Cardiac Inflammation

Post-myocardial infarction studies revealed that Ac-SDKP reduces pro-inflammatory M1 macrophages without affecting M2 macrophages or neutrophils. It also decreases MMP-9 activity, preventing cardiac rupture and improving survival outcomes.

Neurological Inflammation

In experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, Ac-SDKP decreased CD4+ T cell infiltration, reduced astrocyte and microglial activation, and mitigated ER stress markers (caspase-12 and CHOP). This was accompanied by enhanced antioxidant capacity, reduced oxidative stress, and reversal of demyelination in hippocampal tissues.

Antioxidant Capacity

Ac-SDKP demonstrates strong antioxidant effects, lowering ROS and nitric oxide production while restoring glutathione levels and increasing GPx and heme oxygenase activity. These mechanisms collectively reduce oxidative and ER stress, contributing to neuroprotection in demyelinating conditions.

Bone Preservation

Ac-SDKP inhibits osteoclast differentiation through the RANKL signaling pathway, thereby preventing bone mineral density loss in conditions such as silicosis. It also reduces TRAP-positive macrophages and blocks associated inflammatory signaling cascades, protecting against excessive bone resorption.

Clinical Significance

Preclinical and early clinical findings suggest that Ac-SDKP is a potent antifibrotic, anti-inflammatory, and antioxidant agent with broad therapeutic applications. It has demonstrated efficacy in models of kidney disease, cardiomyopathy, pulmonary fibrosis, neuroinflammation, and bone loss. Importantly, it appears well tolerated in humans and may represent a promising adjunct treatment in conditions characterized by chronic inflammation and fibrosis.

See  Also : nad 

REFERENCES

1. Kassem KM, Vaid S, Peng H, Sarkar S, Rhaleb NE. Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system? Can J Physiol Pharmacol. 2019 Jul;97(7):589-599. doi: 10.1139/cjpp-2018-0570. Epub 2019 Mar 9. PMID: 30854877; PMCID: PMC6824425.
2. Cavasin MA, Liao TD, Yang XP, Yang JJ, Carretero OA. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension. 2007 Jul;50(1):130-6. doi: 10.1161/HYPERTENSIONAHA.106.084103. Epub 2007 Apr 30. PMID: 17470726.
3. Li S, Du S, Xue X, Xu D, Xu H, Sun Y, Deng H, Yang Y, Wei Z, Tian J, Yang F. [Inhibition effect of N-acetyl-seryl-aspartyl-lysyl-proline on myofibroblast differentiation of MRC-5 human fetal lung fibroblasts inuced by Ang II]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2014 Nov;32(11):801-5. Chinese. PMID: 25579022.
4. Ac-SDKP increases α-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-β1 and silica
5. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040301